PrimeRFP SCOUT · Federal Contract Recompete Brief

SPE2DP24F12388510325537!adenovirus TYPE 4 a — Teva Pharmaceuticals Usa, Inc

PoP ended Dec 19, 2023 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

Dla Troop Support
Awarding office
Teva Pharmaceuticals Usa, Inc
Recipient
Dec 19, 2023
PoP end
$2.4M
Obligated
$2.4M
Potential
325412
NAICS
6505
PSC

Watch this recompete

One email. No account. We ping you if the window moves.

Contract facts

Federal
Contract numberSPE2DP24F1238
Also listed asSPE2DP-24-F-1238
Also listed asSPE2DP20D0002-SPE2DP24F1238
AgencyDla Troop Support
Awarding officeDla Troop Support
Awarding agencyDepartment of Defense (DOD)
Funding agencyDepartment of Defense (DOD)
IncumbentTeva Pharmaceuticals Usa, Inc
CAGE3V8D7
UEINEN9A34LRHJ5
NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505
Parent IDIQ / IDVSPE2DP20D0002
Place of performancePARSIPPANY NJ
Pricing typeFirm Fixed Price
Extent competedNot Competed
PoP startDec 14, 2023
PoP end (current)Dec 19, 2023
Obligated$2.4M
Current value$2.4M
Potential value$2.4M

8510325537!ADENOVIRUS TYPE 4 A is a federal award for Dla Troop Support held by Teva Pharmaceuticals Usa, Inc. Estimated value $2.4M ($2.4M obligated). Current period of performance ends Dec 19, 2023. Place of performance: PARSIPPANY NJ.

Recompete timing

Public
● Past PoP end (1017 days ago)

Current PoP ended Dec 19, 2023 (1017 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Bonuses end Sept 30

Want the durability read on SPE2DP24F1238? One Pursuit Analysis, $500, inside 48 business hours.

  • 48 business hours
  • $500
  • Credits toward the Pack
Buy one Pursuit Analysis — $500

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

More in SCOUT
Size up the competition →Explore more pipelines →

Frequently asked questions

What is contract SPE2DP24F1238?

SPE2DP24F1238 (8510325537!adenovirus TYPE 4 a) is a Dla Troop Support award with a potential value of $2.4M, currently held by Teva Pharmaceuticals Usa, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is SPE2DP-24-F-1238?

SPE2DP-24-F-1238 is the dashed form of PIID SPE2DP24F1238 (8510325537!adenovirus TYPE 4 a), held by Teva Pharmaceuticals Usa, Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded SPE2DP24F1238?

Dla Troop Support awarded SPE2DP24F1238 to Teva Pharmaceuticals Usa, Inc (potential $2.4M).

Who is the incumbent on SPE2DP24F1238?

Teva Pharmaceuticals Usa, Inc is the incumbent. The current period of performance ends Dec 19, 2023.

When does Teva Pharmaceuticals Usa, Inc’s SPE2DP24F1238 come up for recompete?

SCOUT tracks a period-of-performance end of Dec 19, 2023. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Want the durability read on SPE2DP24F1238? One Pursuit Analysis, $500, inside 48 business hours.

One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.

Get the free Exposure Check

No card · under a minute · then the Sprint menu

Buy one Pursuit Analysis — $500

Credits toward the Sprint Pack

Compare plans

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of · refreshed monthly
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/SPE2DP24F1238